Abbott(US:ABT) Forbes·2025-01-23 17:48Group 1: Market Context - The focus on North American trade, particularly tariffs affecting Canada and Mexico, may benefit stocks with supply chains located elsewhere [1] - The potential for significant stock returns is highlighted, referencing past performance during Trump's first term [2] Group 2: Company Analysis - Analog Devices (ADI) - Analog Devices (ADI) has a strong U.S. manufacturing presence with four facilities, allowing flexibility in production amid trade concerns [3] - The company specializes in semiconductor chips used across various applications, including industrial, automotive, and consumer sectors [4] - ADI is involved in automotive automation, collaborating with Waymo on radar technology for self-driving cars, indicating a strong position in a growing market [5] - The health monitoring sector is another growth area for ADI, with products that integrate various health measurements [6] - ADI's diversified revenue stream ensures no single customer accounts for more than 10% of its revenues, contributing to steady dividend growth, which has increased by 149% over the past decade [7] - Despite a recent 15% pullback, ADI is positioned for potential triple-digit returns as it did during Trump's first term [8] Group 3: Company Analysis - Abbott Laboratories (ABT) - Abbott Laboratories (ABT) experienced a 199% return during Trump's first term, with current trading levels 8% below recent highs due to market fears related to Robert F. Kennedy Jr. [9][10] - The company saw significant sales growth from $32 billion to $45.5 billion, driven by COVID-19 testing kits, although this growth has since subsided [11] - Abbott is focusing on continuous glucose monitoring (CGM) systems, which are gaining traction not only among diabetics but also among health-conscious consumers [12] - The trend towards preventative medicine is expected to grow, positioning Abbott favorably for future demand [14]